Objectives: The macrolide antibiotic roxithromycin has seen widespread clinical use for several decades; however, no population pharmacokinetic analysis has been published. Early studies indicated saturation of protein binding and absorption at doses within the approved range, which may impact pharmacodynamic target attainment since regimens of 150 mg twice daily and 300 mg once daily are used interchangeably in clinical practice. This study aimed to develop a population-based meta-analysis of roxithromycin pharmacokinetics, and utilize this model to inform optimal dosing regimens.
Introduction
The macrolide antibiotic roxithromycin is a well-established agent in the treatment of respiratory tract infections, communityacquired pneumonia, skin and skin structure infections and nongonococcal urethritis. 1, 2 Originally approved in the late 1980s, roxithromycin is a second-generation macrolide derived from erythromycin, offering significant pharmacokinetic advantages, such as improved bioavailability, an extended terminal elimination half-life and a similar spectrum of antibacterial activity. [3] [4] [5] [6] Approved dosing regimens of roxithromycin include 150 mg twice daily or 300 mg once daily taken orally, 7, 8 with no intravenous formulation currently available. 1, 2 Despite widespread clinical use for several decades, no population pharmacokinetic analysis of roxithromycin has been published and, moreover, few studies have investigated pharmacodynamic target attainment with this agent. Furthermore, pharmacokinetic studies of roxithromycin indicated saturation of oral absorption at doses within the approved range, 5, 9, 10 as well as saturation of protein binding to a-1-acid glycoprotein within the normal exposure range. 11, 12 While the approved dosing regimens of 150 mg twice daily and 300 mg once daily would be expected to produce similar total and free drug exposure at steady state in the absence of these factors, it is likely that saturation of absorption and protein binding leads to significant differences in total and free roxithromycin exposure between these dosing regimens. As pharmacodynamic activity is linked to free drug exposure, 13 changes in free roxithromycin exposure may lead to therapeutically significant differences in antibacterial killing. These important clinical questions have not been addressed for roxithromycin.
Population-based meta-analyses to investigate drug pharmacokinetics have been previously reported in the literature. 14, 15 This approach involves the collection and collation of individual-level and aggregate (mean) pharmacokinetic data from literature publications, and the subsequent development of a population pharmacokinetic model. [14] [15] [16] Using this approach, the study reported herein aimed to characterize the pharmacokinetics of roxithromycin, investigate differences in total and free roxithromycin exposure and quantify changes in pharmacodynamic target attainment, with the overall goal of informing optimal dose selection with roxithromycin.
Materials and methods

Pharmacokinetic data collection
An extensive literature search was undertaken via PubMed to identify published roxithromycin pharmacokinetic data in humans up to June 2014. All identified roxithromycin pharmacokinetic data with complete dosing information and defined concentration sampling times were included in the analysis; data with unclear or absent dosing or concentration sampling schedules were excluded. Reference lists of identified publications were hand searched to identify further relevant publications. Individual and aggregate pharmacokinetic data and dosing were collected or digitized from identified publications using DigitizeIt (version 1.5.8). All digitized data were manually inspected during the digitization process to ensure precision and accuracy. Information on pharmacokinetic data included in the analysis, study population and dose range is included in Table 1 .
Population pharmacokinetic modelling
Hierarchical modelling of the pharmacokinetic data was conducted using the maximum likelihood, expectation maximization algorithm (MLEM) in ADAPT (version 5). 17 Model parameters were assumed to be log-normally distributed, while proportional, additive and combined additive and proportional residual error models were considered. Based on a previously described approach, [14] [15] [16] a weighting factor was applied to aggregate pharmacokinetic data included in the model, whereby the proportional residual error was modelled as the inverse of the square root of the number of individuals that contributed data to the pharmacokinetic profile. Model validation was performed with NONMEM 7. 
Model selection and validation
Pharmacokinetic models incorporating either one compartment or two compartments with linear elimination were investigated. Due to the lack of an intravenous formulation, saturation of oral absorption was investigated as changes in relative bioavailability. Model development and selection were guided by goodness-of-fit criteria, including significant decreases in the negative log likelihood (NLL) between nested models, goodness-of-fit plots and precision of parameter estimates. A decrease of 3.84 in NLL (P , 0.05) for one degree of freedom was considered statistically significant. 18 Prediction-corrected visual predictive checks (pcVPCs) were used for model validation. 19 One thousand simulated datasets of individuals from the original dataset were compared with prediction-and variabilitycorrected observed concentrations.
Dosing simulations and pharmacodynamic target attainment
To allow the prediction of free drug roxithromycin exposure given total concentrations, a non-linear expression was constructed using published data on roxithromycin protein binding ( Figure 1 ): 11, 12 Pbound ¼ 21:5 þ 74:3=ð1 þ e 6:43ðCÀ3:20Þ Þ 0:00489 ; C ! 3:20 mg=L (Figure 1) .
To quantify exposure differences between roxithromycin dosing regimens, total and free roxithromycin exposures at the approved dosing regimens of 150 mg twice daily and 300 mg once daily were simulated using Monte Carlo simulations in ADAPT for 1000 individuals. To investigate total and free roxithromycin at higher doses, 450 mg daily and 300 mg twice daily regimens were simulated. Using these simulations, pharmacodynamic target attainment on day 7 of therapy was predicted as the proportion of individuals achieving a pharmacodynamic target of an fAUC/MIC ratio .20, associated with optimal antibacterial activity. 20 Proportions were evaluated with decreasing pathogen susceptibility (increasing MIC), and against MIC distributions for pathogens commonly treated with roxithromycin obtained from EUCAST. 21 
Results
Model development and validation
A total of 40 aggregate and 23 individual roxithromycin concentration-time profiles across a 6-fold dose range were included in the analysis (Table 1) . A two-compartment model with dose-dependent first-order absorption and first-order elimination adequately described the dataset; other absorption and elimination models, such as zero-order absorption, mixed-order absorption or elimination did not improve goodness of fit.
Parameter estimates and associated standard errors for the structural model, interindividual variability and residual variability from the final model are shown in Table 2 . Based on data inspection, roxithromycin oral absorption was found to be dose-proportional at doses up to 150 mg; 9 hence saturation of absorption was characterized by the equation: where F50 is the roxithromycin dose associated with a halfmaximal reduction in relative bioavailability and FImax is the maximal reduction in relative bioavailability. Based on the observed less than dose-proportional increases in roxithromycin AUC, FImax was fixed to 0.5, and consequently F50 is interpreted as the roxithromycin dose associated with a 25% reduction in relative bioavailability. The population estimate of F50 in the final model was 250 mg, with significant interindividual variability [coefficient of variation (CV) 65.7%]. High interindividual variability was also observed in distributional clearance (CV 79.9%) and peripheral volume (CV 62.6%). Goodness-of-fit plots and pcVPCs used throughout model development indicated satisfactory model fit (Figure 2 ). The pcVPC of the final model ( Figure 3 ) indicated good predictive performance, with suitable agreement between prediction-and variabilitycorrected observed data and model-simulated CIs for the median and the 2.5th and 97.5th percentiles.
Due to the inclusion of aggregate-level pharmacokinetic data, low frequency of potential covariate effects and study heterogeneity, it was not feasible to perform a covariate analysis.
Dosing simulations and target attainment
Total and free roxithromycin exposure on day 7 with approved and higher dose regimens is shown in Figure 4 (n " 5000 simulated individuals). Between approved roxithromycin dosing regimens, total roxithromycin exposure was 37% lower with 300 mg daily dosing (median 104, IQR 30.7 mgÁh/L) than with 150 mg twice daily dosing (median 165, IQR 84.9 mgÁh/L). A larger difference was observed with free roxithromycin exposure, which was found to be 53% lower with 300 mg daily dosing (median 10 Pharmacodynamic target attainment on day 7 of therapy with approved and higher-dose roxithromycin regimens is shown in Figure 5 (a), and predicted median and 2.5th and 97.5th percentiles of fAUC/MIC for approved dosing regimens are shown in Figure 5(b) . Among the approved roxithromycin dosing regimens, target attainment was similar up to an MIC of 0.25 mg/L, with .95% of individuals achieving an fAUC/MIC .20. At MICs of 0.5 and 1 mg/L, 51% and 7% of patients receiving 300 mg once daily achieved an adequate fAUC/MIC, respectively, compared with 82% and 54% of patients receiving 150 mg twice daily. In comparison with pathogens commonly treated with roxithromycin, these differences are unlikely to be clinically relevant for Streptococcus pyogenes, with a distribution centred on an MIC of 0.064 mg/L, but may be clinically important for Staphylococcus aureus, which has an MIC distribution centred on an MIC of 0.5 mg/L. 21 Among higher dose regimens, 450 mg daily led to target attainment broadly similar to the approved 150 mg twice daily regimen, whereas 300 mg twice daily resulted in higher target attainment at MICs of 0.5, 1 and 2 mg/L.
Discussion
Using a population-based meta-analysis approach, this study represents the first population pharmacokinetic analysis of roxithromycin, and highlights significant differences in roxithromycin exposure and pharmacodynamic target attainment between approved dosing regimens for this medicine.
Due to the effect of saturable oral absorption, significantly lower total roxithromycin exposure was observed with 300 mg daily dosing compared with the 150 mg twice daily regimen (Figure 4) . Further, this reduction in exposure was larger when considering free roxithromycin exposure, with the 300 mg once daily regimen leading to less than half the free roxithromycin exposure resulting from the 150 mg twice daily regimen. This larger impact on free drug exposure, as opposed to total exposure, indicates that saturation of roxithromycin protein binding exacerbates the reduction in exposure that can be attributed to saturable absorption. These results translated to a significantly higher proportion of Dolton and D'Argenio patients achieving the pharmacodynamic target for pathogens at MIC values of 0.5 and 1 mg/L among patients receiving 150 mg twice daily compared with 300 mg daily. While the potential clinical relevance of these findings is difficult to predict, it is noteworthy that these differences occur within the typical range of MIC values for some commonly treated pathogens for roxithromycin, such as S. aureus. Accordingly, the observed pharmacokinetic differences between the approved dosing regimens for Roxithromycin population pharmacokinetics JAC roxithromycin might lead to differences in clinical efficacy for pathogens within this MIC range.
To investigate the effectiveness of higher-dose roxithromycin regimens in increasing exposure, roxithromycin dosing regimens of 450 or 300 mg twice daily were investigated. Between these regimens, 450 mg daily does not improve free drug exposure beyond the level observed with the 150 mg twice daily regimen, whereas 300 mg twice daily leads to a 63% increase in free Figure 5 . (a) Predicted pharmacodynamic target attainment on day 7 of treatment with approved dosing regimens (150 mg twice daily or 300 mg daily; continuous lines) or higher dose regimens (450 mg daily or 300 mg twice daily; broken lines), shown as the proportion of individuals achieving an fAUC/MIC .20 (n " 1000). The MIC distributions of S. aureus (n " 4001 isolates) and S. pyogenes (n " 53 isolates) for roxithromycin are also shown. 21 (b) Predicted median and 2.5th and 97.5th percentiles of fAUC/MIC ratios with approved dosing regimens (150 mg twice daily or 300 mg daily). q12h, every 12 h; q24h, every 24 h. roxithromycin concentrations. This increase in free roxithromycin exposure translates to a higher proportion of individuals achieving the pharmacodynamic target with pathogen MICs of 0.5, 1 and 2 mg/L. While clinical experience with roxithromycin daily doses exceeding 300 mg appears to be very limited, 5, 22 these results provide guidance that a twice-daily dosing regimen is preferred if higher roxithromycin exposure is required in a particular clinical situation.
A population-based meta-analysis approach was used to develop the roxithromycin population pharmacokinetic model in this study, utilizing literature publications to collate and combine individual-level and aggregate pharmacokinetic data. While the necessary pharmacokinetic data to support this model could alternatively have been generated through a dose-ranging healthy volunteer study, the meta-analysis approach utilizes existing, publicly available information and, when appropriate, may be a viable strategy to inform clinical practice at a substantially lower cost. This approach has been utilized with several other medicines, 14, 15, 23 and is likely to have greater utility with established medicines, where a wealth of published pharmacokinetic information is often available. This technique may be particularly useful in the pharmacokinetic interrogation of medicines approved before the modern era of drug development, integrating existing individual and aggregate pharmacokinetic data to inform pressing clinical questions without the need for additional clinical studies.
In conclusion, roxithromycin displays saturable absorption and protein binding, leading to significantly lower exposure following once-daily dosing compared with twice-daily regimens. This pharmacokinetic difference translates to important differences in target attainment for pathogens with MICs !0.5 mg/L, indicating that twice-daily roxithromycin regimens may be preferable for pathogens less susceptible to roxithromycin. 
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